Phase 1 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+ B-Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy
Rajat Bannerji(Rutgers, The State University of New Jersey), Carrie Brownstein(Regeneron (United States)), Jennifer R. Brown(Dana-Farber Cancer Institute), Jon Arnason(Beth Israel Deaconess Medical Center), John N. Allan(Cornell University), Jeffrey A. Barnes(Harvard University), Robin Joyce(Beth Israel Deaconess Medical Center), Lieve Adriaens(Regeneron (United States)), Israel Lowy(Bristol-Myers Squibb (Germany)), Melanie Ufkin(Regeneron (United States)), Pamela A. Trail(Ophthalmic Consultants of Long Island), Stephen M. Ansell(Mayo Clinic), Ranjana H. Advani(Stanford Medicine), Bo Gao(Regeneron (United States)), Anne Paccaly(Regeneron (United States)), Julio C. Chávez(Moffitt Cancer Center), Max S. Topp(Universitätsklinikum Würzburg), Ana Kostić(Regeneron (United States)), Susan O’Brien(University of California, Irvine)
Cited by 19
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k